A Phase I Study of NMS-03597812 in People with Multiple Myeloma


Full Title

A Phase I Dose Escalation Study of NMS-03597812, a PERK inhibitor, in Adult Patients with Relapsed or Refractory Multiple Myeloma


The purpose of this study is to find the highest dose of the investigational drug NMS-03597812 that can be given safely in people with multiple myeloma that continues to grow despite treatment. NMS-03597812 blocks a protein called PERK that can help multiple myeloma cells grow and survive. By blocking this protein, NMS-03597812 may slow or stop the growth of multiple myeloma. It is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have multiple myeloma that came back or continued to grow despite at least three or more regimens of treatment.
  • The serious side effects of previous treatments should get better before patients can receive NMS-03597812.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Dr. Hani Hassoun at 646-608-3718.





Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID